A probability/risk matrix of febrile neutropenia to select patients for G-CSF primary prophylaxis

被引：0
|
作者：
Ramchandani Vaswani, A. [1 ]
Faez, L. [2 ]
Selvi Miralles, M. [3 ]
Antonio-Rebollo, M. [4 ]
Font Puig, C. [3 ]
Espinosa Arranz, J. [5 ]
Biosca, M. [6 ]
Vicente Rubio, E. [7 ,8 ]
Jimenez Fonseca, P. [2 ]
Carmona-Bayonas, A.
机构：
[1] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain
[2] Hosp Cent Asturias, Oviedo, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] ICO Duran & Reynals, Barcelona, Spain
[5] Hosp Gen Ciudad Real, Ciudad Real, Spain
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Hosp Univ Insular Gran Canaria, Barcelona, Spain
[8] Hosp Univ Morales Meseguer, Murcia, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1326
引用
收藏
页码：S275 / S276
页数：2
相关论文
共 50 条
  • [21] Discrete Choice Experiment to Estimate Physicians' Preferences in Terms of G-CSF use for Febrile Neutropenia Primary and Secondary Prophylaxis
    Chouaid, C.
    Scotte, F.
    Antoine, E.
    Simon, H.
    Texier, N.
    Laplaige, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S201 - S201
  • [22] The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis
    Do, Tran
    Medhekar, Rohan
    Bhat, Raksha
    Chen, Hua
    Niravath, Polly
    Trivedi, Meghana V.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) : 591 - 597
  • [23] G-CSF for prophylaxis of neutropenia and febrile neutropenia, anemia in cancer. Guidelines on supportive treatment part 1
    Link, Hartmut
    [J]. UROLOGIE, 2022, 61 (05): : 537 - 549
  • [24] Discrete Choice Experiment to estimate physicians' Preferences in terms of G-CSF use for febrile neutropenia primary and secondary prophylaxis
    Scotte, F.
    Antoine, E-C.
    Simon, H.
    Texier, N.
    Laplaige, P.
    Chouaid, C.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1072 - S1072
  • [25] Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors
    Laali, Elahe
    Fazli, Jinous
    Sadighi, Sanambar
    Mohammadi, Mehdi
    Gholami, Kheirollah
    Jahangard-Rafsanjani, Zahra
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) : 428 - 433
  • [26] The occurrence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer not receiving primary G-CSF prophylaxis
    Hutajulu, Susanna Hilda
    Oktariani, Siswi
    Sunggoro, Agus Jati
    Bintoro, Bagas Suryo
    Astari, Yufi Kartika
    Wiranata, Juan Adrian
    Widodo, Irianiwati
    Ekowati, Anita
    Hardianti, Mardiah Suci
    Taroeno-Hariadi, Kartika Widayati
    Kurnianda, Johan
    Purwanto, Ibnu
    [J]. ECANCERMEDICALSCIENCE, 2023, 17
  • [27] A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia
    Lalami, Y
    Paesmans, M
    Aoun, M
    Munoz-Bermeo, R
    Reuss, K
    Cherifi, S
    Alexopoulos, CG
    Klastersky, J
    [J]. SUPPORTIVE CARE IN CANCER, 2004, 12 (10) : 725 - 730
  • [28] A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia
    Y. Lalami
    M. Paesmans
    M. Aoun
    R. Munoz-Bermeo
    K. Reuss
    S. Cherifi
    C. G. Alexopoulos
    J. Klastersky
    [J]. Supportive Care in Cancer, 2004, 12 : 725 - 730
  • [29] PREDICTORS OF G-CSF PROPHYLAXIS IN THE FIRST CYCLE OF CHEMOTHERAPY FOR FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
    Lugtenburg, P.
    Asubonteng, J.
    DeCosta, L.
    Szabo, Z.
    Page, J. H.
    Wetten, S.
    [J]. HAEMATOLOGICA, 2014, 99 : 196 - 196
  • [30] Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with long-acting G-CSF in patients treated with chemotherapy in Germany: results of the epidemiological cross-sectional survey "G-CSF Day"
    Egerer, G.
    Uleer, C.
    Klausmann, M.
    Lueck, A.
    Schroeder, J.
    Schulz, H.
    Fichter, C.
    von der Heyde, E.
    Voss, P.
    Worth, G.
    Burbeck, M.
    Sahlmann, J.
    Potthoff, K.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 261 - 261
12345